Augmentation of ITGAE (CD103
), a known marker of memory T-cell activation in EBSC cohort was also observed.
Phenotypically, Treg cells express FOXP3, cytotoxic T lymphocyte-associated antigen-4 (CTLA4), certain members of toll-like receptors, CD103
([alpha]E[beta]7integrin), glucocorticoid-induced TNF receptor family-related gene (GITR), lymphocyte activation gene-3, programmed death receptor-1, and neurophilin on their surface (9, 10).
Several groups have shown that CD103
, also known as integrin aE, is expressed on a subset of CD8(+) TILs in multiple solid human tumors (including ovarian, lung, cervical, and head and neck cancer patients cancer as well as endometrial adenocarcinoma) and it is known that its expression is induced upon TCR engagement and exposure to TGF-[beta]1 [67-72].
The cells also typically express CD103
, CD11c, and CD25 but usually not CD5, CD10, or CD23.
These cells exhibited phenotypic characteristics of Tregs, confirmed by the expression of CTLA-4, GITR, CD103
, CD45RO, and Foxp3 .
(57) Hairy cell leukemia is positive for all common B-cell antigens (CD19, CD20, CD79a, FMC-7, and PAX5), with characteristic expression of annexin A1 (Figure 7, A), CD11c, CD25, CD103
, CD123, DBA-44 (CD72) (Figure 7, B), the Hector Battifora mesothelial epitope-1 (HBME-1), pERK, Tbet, and TRAP58-61 but is typically negative for CD5 and CD10, although 10% to 20% of HCLs are positive for CD10.
(44) These Tregs express CD103
, CCR4, and CCR5, but the molecular mechanism underlying their migration from the skin to lymph nodes remains unclear.
In all cases, an immunophenotypic analysis was performed by flow cytometry, including CD19, CD5, CD22, CD23, CD38, CD25, CD103
, CD11c, FMC7, BCL2, CD10, CD20, and surface immunoglobulins ?
DCs can regulate obesity-induced inflammation in AT by influencing the balance of Treg and Th17 cell differentiation in vivo remains unknown .
The neoplastic lymphoid cells were negative for CD5, CD11c, and CD103
. Hence the diagnosis of B cell non-Hodgkin lymphoma (low grade follicular lymphoma) was made.
FITC-conjugated anti-mouse CD103
, PE-conjugated anti-mouse I-A/I-E (MHC-II), PE-conjugated anti-mouse CD4, PerCP-conjugated anti-mouse CD25, and PE-conjugated anti-mouse FOXP3 were supplied by BioLegend Company.
The neoplastic cells stained positive for CD45, CD19, CD20, CD11c, CD22, CD25, and CD103
, consistent with hairy cell leukemia.